Dr Sally Martin

Lecturer

School of Biomedicine

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

Dr Martin is currently a post-doctoral researcher in the Myeloma Research Laboratory, School of Medical Sciences, University of Adelaide, based at the SAHMRI, Cancer Theme.

Dr Martin's PhD research, completed in 2009, centred on bone marrow angiogenesis and osteolytic bone disease in the haematological malignancy, multiple myeloma. Since completing her PhD studies, Dr Martin has been examining the role of the PI3K and mTOR signalling pathways in bone development, looking at ways to exploit these pathways to stimulate bone formation in disease settings such as osteoporosis and tumour-associated bone loss.

Dr Martin is an affiliate lecturer in the School of Medical Sciences and the School of Medicine, University of Adelaide.

Dr Martin's current research projects are focussed on (1) the role of the mTOR signalling pathways in mesenchymal stem cell biology, (2) the role of the mTOR signalling pathways in regulating skeletal biology and bone remodelling, and (3) the role of skeletal mTORC1 signalling in B-cell development and glucose homeostasis.

Career
Publications
Grants and Funding
Supervision
Contact

Appointments

Date	Position	Institution name
2015 - ongoing	Post-doctoral Researcher	University of Adelaide, Adelaide
2013 - ongoing	Affiliate Lecturer	University of Adelaide
2012 - ongoing	Affiliate Lecturer	University of Adelaide
2009 - 2015	Post-doctoral Researcher	SA Pathology
2003 - 2008	Technical Assistant (part-time)	Institute of Medical and Veterinary Science (IMVS)

Education

Date	Institution name	Country	Title
2005 - 2008	University of Adelaide, Adelaide	Australia	PhD
2000 - 2004	University of South Australia	Australia	Bachelor of Medical and Pharmaceutical Biotechnology (Hons)

Journals

Year	Citation
2021	Tangseefa, P., Martin, S. K., Chin, P. Y., Breen, J., Mah, C. Y., Baldock, P. A., . . . Zannettino, A. C. W. (2021). The mTORC1 complex in pre-osteoblasts regulates whole-body energy metabolism independently of osteocalcin. Bone Research, 9(1), 10-1-10-17. DOI Scopus2 WoS3 Europe PMC3
2021	Tangseefa, P., Martin, S. K., Arthur, A., Panagopoulos, V., Page, A. J., Wittert, G. A., . . . Zannettino, A. C. W. (2021). Deletion of Rptor in preosteoblasts reveals a role for the mammalian target of rapamycin complex 1 (mTORC1) complex in dietary-induced changes to bone mass and glucose homeostasis in female mice. JBMR Plus, 5(5), 1-14. DOI Scopus1
2020	Xie, J., Shen, K., Jones, A. T., Yang, J., Tee, A. R., Shen, M. H., . . . Proud, C. G. (2020). Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis.. Cellular and molecular life sciences : CMLS, 78(1), 249-270. DOI Scopus11 WoS10 Europe PMC6
2018	Martin, S., Fitter, S., El Khawanky, N., Grose, R., Walkley, C., Purton, L., . . . Zannettino, A. (2018). mTORC1 plays an important role in osteoblastic regulation of B-lymphopoiesis. Scientific Reports, 8(1), 14501-1-14501-10. DOI Scopus13 WoS12 Europe PMC10
2018	Tangseefa, P., Martin, S., Fitter, S., Baldock, P., Proud, C., & Zannettino, A. (2018). Osteocalcin-dependent regulation of glucose metabolism and fertility: skeletal implications for the development of insulin resistance. Journal of Cellular Physiology, 233(5), 3769-3783. DOI Scopus15 WoS13 Europe PMC8
2017	Vandyke, K., Zeissig, M., Hewett, D., Martin, S., Mrozik, K., Cheong, C., . . . Zannettino, A. (2017). HIF-2α promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12/CXCR4 and CCR1. Cancer Research, 77(20), 5452-5463. DOI Scopus36 WoS36 Europe PMC25
2017	Fitter, S., Matthews, M., Martin, S., Xie, J., Ooi, S., Walkley, C., . . . Zannettino, A. (2017). mTORC1 plays an important role in skeletal development by controlling preosteoblast differentiation. Molecular and Cellular Biology, 37(7), e00668-1-e00668-20. DOI Scopus44 WoS39 Europe PMC33
2015	Gan, Z., Fitter, S., Vandyke, K., To, L., Zannettino, A., & Martin, S. (2015). The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. European Journal of Haematology, 94(4), 343-354. DOI Scopus29 WoS27 Europe PMC21
2015	Martin, S., Fitter, S., Dutta, A., Matthews, M., Walkley, C., Hall, M., . . . Zannettino, A. (2015). Brief report: The differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiation. Stem Cells, 33(4), 1359-1365. DOI Scopus70 WoS67 Europe PMC58
2015	Martin, S., Gan, Z., Fitter, S., To, L., & Zannettino, A. (2015). The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma. Leukemia Research, 39(3), 380-387. DOI Scopus20 WoS18 Europe PMC14
2015	Cheong, C., Chow, A., Fitter, S., Hewett, D., Martin, S., Williams, S., . . . Vandyke, K. (2015). Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo. Experimental Cell Research, 332(1), 24-38. DOI Scopus23 WoS24 Europe PMC18
2015	Forristal, C., Brown, A., Helwani, F., Winkler, I., Nowlan, B., Barbier, V., . . . Levesque, J. (2015). Hypoxia inducible factor (HIF)-2α accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AML. Leukemia, 29(10), 2075-2085. DOI Scopus24 WoS27 Europe PMC24
2011	Martin, S., Diamond, P., Gronthos, S., Peet, D., & Zannettino, A. (2011). The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia, 25(10), 1533-1542. DOI Scopus100 WoS93 Europe PMC82
2010	Martin, S., Fitter, S., Bong, L., Drew, J., Gronthos, S., Shepherd, P., & Zannettino, A. (2010). NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. Journal of Bone and Mineral Research, 25(10), 2126-2137. DOI Scopus53 WoS51 Europe PMC43
2010	Williams, S., Martin, S., Vincent, C., Gronthos, S., Zheng, T., Atkins, G., & Zannettino, A. (2010). Circulating levels of TWEAK correlate with bone erosion in multiple myeloma patients. British Journal of Haematology, 150(3), 373-376. DOI Scopus6 WoS6 Europe PMC3
2010	Martin, S., Diamond, P., Williams, S., To, L., Peet, D., Fujii, N., . . . Zannettino, A. (2010). Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica, 95(5), 776-784. DOI Scopus76 WoS72 Europe PMC54
2010	Psaltis, P., Paton, S., See, F., Arthur, A., Martin, S., Itescu, S., . . . Zannettino, A. (2010). Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations. Journal of Cellular Physiology, 223(2), 530-540. DOI Scopus119 WoS113 Europe PMC88
2009	Diamond, P., Labrinidis, A., Martin, S., Farrugia, A., Gronthos, S., To, L., . . . Zannettino, A. (2009). Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. Journal of Bone and Mineral Research, 24(7), 1150-1161. DOI Scopus58 WoS59 Europe PMC43
2009	Labrinidis, A., Diamond, P., Martin, S., Hay, S., Liapis, V., Zinonos, I., . . . Evdokiou, A. (2009). Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clinical Cancer Research, 15(6), 1998-2009. DOI Scopus32 WoS30 Europe PMC27
2006	Martin, S., Dewar, A., Farrugia, A., Horvath, N., Gronthos, S., To, L., & Zannettino, A. (2006). Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1α in patients with multiple myeloma. Clinical Cancer Research, 12(23), 6973-6977. DOI Scopus33 WoS30 Europe PMC21
2005	Zannettino, A., Farrugia, A., Kortesidis, A., Manavis, J., To, L., Martin, S., . . . Gronthos, S. (2005). Elevated serum levels of stromal-derived factor-1α are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Research, 65(5), 1700-1709. DOI Scopus176 WoS164 Europe PMC119
2004	Martin, S., To, L., Horvath, N., & Zannettino, A. (2004). Angiogenesis in multiple myeloma: Implications in myeloma therapy. Cancer Reviews: Asia-Pacific, 2(2), 119-129. DOI

Book Chapters

Year	Citation
2008	Zannettino, A., Martin, S. K., Gronthos, S., To, L., & Peet, D. (2008). The role of CXCL12 in multiple myeloma. In F. columbus (Ed.), Cancer Research Progress. Nova Science Publishers.

Conference Papers

Year	Citation
2018	Tangseefa, P., Martin, S. K., Wilczek, V., Baldock, P., Proud, C. G., Fitter, S., & Zannettino, A. C. W. (2018). Metabolic and reproductive abnormalities in mice with impaired skeletal-mTORC1 function mirror a dietary restriction phenotype. In CLINICAL ENDOCRINOLOGY Vol. 89 (pp. 19). Perth, AUSTRALIA: WILEY.
2017	Zeissig, M. N., Hewett, D. R., Martin, S., Mrozik, K. M., Cheong, C. M., Diamond, P., . . . Zannettino, A. C. W. (2017). HIF-2 alpha Upregulates CCR1 to Promote Dissemination of Plasma Cells in Multiple Myeloma. In BLOOD Vol. 130 (pp. 2 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
2013	Forristal, C. E., Helwani, F., Martin, S., Nowlan, B., Winkler, I. G., Zannettino, A., & Levesque, J. -P. (2013). Hypoxia Inducible Factor (HIF)-2 alpha Enhances Proliferation Of Malignant Hematopoietic Cells In The Hypoxic Malignant Bone Marrow. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY. DOI WoS1
2008	Martin, S. K., Diamond, P., To, L. B., Pect, D., Gronthos, S., & Zannettino, A. W. W. (2008). CXCL12 Expression Is Regulated by HIF-2a in Multiple Myeloma Plasma Cells. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 23 (pp. S262). Montreal, CANADA: AMER SOC BONE & MINERAL RES.
2008	Diamond, P., Labrinidis, A., Martin, S. K., Farrugia, A., Gronthos, S., To, L. B., . . . Zannettino, A. (2008). CXCL12 stimulates osteoclastic bone resorption in a novel mouse model of human multiple myeloma. In Journal of Bone and Mineral Research Vol. 23 (pp. S262). Montreal: American Society for Bone and Mineral Research.
2007	Martin, S. K., Dewar, A., Farrugia, A., Horvath, N., Gronthos, S., To, L. B., & Zannettino, A. (2007). Tumour angiogenesis is associated with plasma levels of stromal-derived factor-1a in patients with multiple myeloma. In Haematologica Vol. 92 (pp. 125-126). Kos, Greece: Ferrata Storti Foundation.
2007	Martin, S. K., Dewar, A. L., Farrugia, A. N., Horvath, N., Gronthos, S., To, L. B., & Zannettino, A. C. W. (2007). Tumour angiogenesis correlates with plasma levels of CXCL12 in patients with multiple myeloma. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 92 (pp. 125-126). Kos Isl, GREECE: FERRATA STORTI FOUNDATION.
2007	Diamond, P., Labrinidis, A., Martin, S. K., Farrugia, A. N., Gronthos, S., To, L. B., . . . Zannettino, A. C. W. (2007). CXCL12 stimulates osteoclastic bone resorption in a novel mouse model of human multiple myeloma. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 92 (pp. 130). Kos Isl, GREECE: FERRATA STORTI FOUNDATION.

Conference Items

Year	Citation
2013	Forristal, C., Helwani, F., Nowlan, B., Martin, S., Zannetino, A., & Levesque, J. -P. (2013). HYPOXIA INDUCIBLE FACTOR (HIF)-2 alpha ENHANCES PROLIFERATION OF MALIGNANT HAEMATOPOIETIC CELLS IN THE HYPOXIC MALIGNANT BONE MARROW. Poster session presented at the meeting of EXPERIMENTAL HEMATOLOGY. Vienna, AUSTRIA: ELSEVIER SCIENCE INC. DOI

Mary Overton Early Career Research Fellowship (2012 - 2015), The role of the raptor and rictor signalling pathways in skeletal biology, AUD$252,000

Centre for Stem Cell Research Project Grant 2012, The role of raptor and rictor in MSC differentiation, AUD$75,000

Novartis Pharmaceuticals Project Grant 2011, Can the dual PI3K/mTOR inhibitor NVP-BEZ235 be used to stimulate bone formation in multiple myeloma? AUD$75,000.

Past Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2017 - 2020	Co-Supervisor	The Role of Osteoblast-mTORC1 in the Regulation of Glucose Metabolism	Doctor of Philosophy	Doctorate	Full Time	Miss Pawanrat Tangseefa
2013 - 2018	Co-Supervisor	The Role of mTORC1 in Mesenchymal Stem Cell Fate Determination, Osteoblast Differentiation and Skeletal Development	Doctor of Philosophy	Doctorate	Part Time	Ms Mary Patricia Matthews

Position: Lecturer
Email: sally.martin@adelaide.edu.au
Campus: North Terrace
Building: Helen Mayo North, floor 2
Org Unit: Medical Sciences